{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:16:04Z","timestamp":1778580964779,"version":"3.51.4"},"reference-count":90,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"King's College London"},{"name":"Guy's and St Thomas' NHS Foundation Trust"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Acute recreational drug toxicity (ARDT) is a frequent cause of emergency department presentations; however, clinicians lack guidance for interpreting drug concentrations. Existing terminology (\u201ctherapeutic,\u201d \u201ctoxic,\u201d and \u201clethal\u201d) does not reflect the variability observed in ARDT, where tolerance, interindividual differences, and polydrug exposure influence clinical features. This study aimed to develop a descriptive, clinician-oriented framework to categorize illicit and prescription drug concentrations into meaningful interpretive bands.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A literature search identified studies reporting antemortem plasma concentrations in adults. Twenty-four analytes (parent drugs and metabolites) commonly detected in ARDT were included. Concentrations were standardized to ng\/mL. For illicit drugs, skewness, histograms, and robust z-scores (median absolute deviation\u2013based; threshold \u00b13.5) were used to identify and remove outliers. Interquartile- or tertile-based interpretive bands (low, moderate, and high) were assigned according to data set characteristics. Gamma-hydroxybutyrate concentrations were classified using endogenous cutoff values. Prescription medicines were categorized as within or above the therapeutic range based on established reference ranges.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thousand two hundred sixteen plasma concentrations from 79 studies met the inclusion criteria. Illicit drug ranges included analytes with narrow (ketamine, 53\u201386 ng\/mL) and broad (cocaine, 65\u2013193 ng\/mL) concentration\u2013effect variability. The endogenous cutoff for gamma-hydroxybutyrate was 5000 ng\/mL. Prescription medicine ranges reflected expected therapeutic patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This study proposes a reproducible, percentile-based framework for interpreting plasma drug concentrations in ARDT. The framework provides clinically intuitive, data-driven reference bands to support clinical interpretation, enhance communication between laboratories and clinicians, and offer a scalable foundation for future guideline development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001471","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:02:10Z","timestamp":1777892530000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Interpretive Reference Ranges for Plasma Drug Concentrations in Acute Recreational Drug Toxicity: A Short Communication"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0058-7161","authenticated-orcid":false,"given":"Stefania","family":"Boccuzzi","sequence":"first","affiliation":[{"name":"Department of Analytical, Environmental and Forensic Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Battal","sequence":"additional","affiliation":[{"name":"Department of Toxicology, Faculty of Pharmacy, Mersin University, Mersin, Turkey;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Cowan","sequence":"additional","affiliation":[{"name":"Department of Analytical, Environmental and Forensic Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul I.","family":"Dargan","sequence":"additional","affiliation":[{"name":"Clinical Toxicology, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom; and"},{"name":"Clinical Toxicology, Guy's and St Thomas' NHS Foundation Trust and King's Health Partners, London, United Kingdom."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-0520","authenticated-orcid":false,"given":"Vincenzo","family":"Abbate","sequence":"additional","affiliation":[{"name":"Department of Analytical, Environmental and Forensic Sciences, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/qjmed\/hcr074","article-title":"Survey of ICD-10 coding of hospital admissions in the UK due to recreational drug toxicity","volume":"104","author":"Shah","year":"2011","journal-title":"QJM"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s13054-020-02915-5","article-title":"Revisited: therapeutic and toxic blood concentrations of more than 1100 drugs and other xenobiotics","volume":"24","author":"Schulz","year":"2020","journal-title":"Crit Care"},{"key":"R5-20260508","first-page":"298","article-title":"The molecular basis of tolerance","volume":"31","author":"Pietrzykowski","year":"2008","journal-title":"Alcohol Res Health"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/wsbm.1302","article-title":"Parsing interindividual drug variability: an emerging role for systems pharmacology","volume":"7","author":"Turner","year":"2015","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.3390\/jcm12185970","article-title":"Determinants of admission to critical care following acute recreational drug toxicity: a Euro-DEN plus study","volume":"12","author":"Noseda","year":"2023","journal-title":"J Clin Med"},{"key":"R8-20260508","doi-asserted-by":"crossref","first-page":"101705","DOI":"10.1016\/j.toxrep.2024.101705","article-title":"Assessment of co-ingestion effects on poisoning patterns, drug-drug interactions, and adverse outcomes in acute toxic exposure","volume":"13","author":"Sharif","year":"2024","journal-title":"Toxicol Rep"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.jesp.2013.03.013","article-title":"Detecting outliers: do not use standard deviation around the mean, use absolute deviation around the median","volume":"49","author":"Leys","year":"2013","journal-title":"J Exp Soc Psychol"},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0379-0738(03)00043-4","article-title":"Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production","volume":"133","author":"Elliott","year":"2003","journal-title":"Forensic Sci Int"},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S0379-0738(02)00183-4","article-title":"Determination of endogenous gamma-hydroxybutyric acid (GHB) levels in antemortem urine and blood","volume":"128","author":"Elian","year":"2002","journal-title":"Forensic Sci Int"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/15563650.2018.1519194","article-title":"Interpreting \u03b3-hydroxybutyrate concentrations for clinical and forensic purposes","volume":"57","author":"Busard\u00f2","year":"2019","journal-title":"Clin Toxicol"},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/jat\/25.7.531","article-title":"Simultaneous determination of \u03949-tetrahydrocannabinol and 11-nor-9-carboxy-\u03949-tetrahydrocannabinol in human plasma by solid-phase extraction and gas chromatography-negative ion chemical ionization-mass spectrometry","volume":"25","author":"Huang","year":"2001","journal-title":"J Anal Toxicol"},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/jat\/28.6.394","article-title":"Relationship of \u03949-tetrahydrocannabinol concentrations in oral fluid and plasma after controlled administration of smoked cannabis","volume":"28","author":"Huestis","year":"2004","journal-title":"J Anal Toxicol"},{"key":"R17-20260508","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/BF00427095","article-title":"Clinical effects and plasma levels of delta 9-tetrahydrocannabinol (delta 9-THC) in heavy and light users of cannabis","volume":"74","author":"Lindgren","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"R18-20260508","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jat\/25.7.538","article-title":"Temporal indication of marijuana use can be estimated from plasma and urine concentrations of delta9-tetrahydrocannabinol, 11-hydroxy-delta9-tetrahydrocannabinol, and 11-nor-delta9-tetrahydrocannabinol-9-carboxylic acid","volume":"25","author":"Manno","year":"2001","journal-title":"J Anal Toxicol"},{"key":"R19-20260508","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jat\/29.8.782","article-title":"Simultaneous and sensitive analysis of THC, 11-OH-THC, THC-COOH, CBD, and CBN by GC-MS in plasma after oral application of small doses of THC and cannabis extract","volume":"29","author":"Nadulski","year":"2005","journal-title":"J Anal Toxicol"},{"key":"R20-20260508","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00414-018-1797-5","article-title":"Comparison of concentrations of drugs between blood samples with and without fluoride additive-important findings for \u0394(9)-tetrahydrocannabinol and amphetamine","volume":"133","author":"Wiedfeld","year":"2019","journal-title":"Int J Leg Med"},{"key":"R21-20260508","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.1980.181","article-title":"Plasma delta-9 tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking","volume":"28","author":"Ohlsson","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"R22-20260508","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/jat\/33.8.469","article-title":"Implications of plasma Delta9-tetrahydrocannabinol, 11-hydroxy-THC, and 11-nor-9-carboxy-THC concentrations in chronic cannabis smokers","volume":"33","author":"Karschner","year":"2009","journal-title":"J Anal Toxicol"},{"key":"R23-20260508","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s40263-025-01189-1","article-title":"Pharmacokinetics and pharmacodynamics of intranasal diacetylmorphine in heroin-assisted treatment for severe opioid use disorder","volume":"39","author":"Guessoum","year":"2025","journal-title":"CNS Drugs"},{"key":"R24-20260508","doi-asserted-by":"crossref","first-page":"486","DOI":"10.5414\/CPP38486","article-title":"Pharmacodynamics and pharmacokinetics of intravenously, orally and rectally administered diacetylmorphine in opioid dependents, a two-patient pilot study within a heroin-assisted treatment program","volume":"38","author":"Gyr","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R25-20260508","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1081\/JLC-100102050","article-title":"Diacetylmorphine and its metabolites in plasma by HPLC with diode-array and atmospheric pressure ionization mass spectrometric detection","volume":"22","author":"Bourquin","year":"1999","journal-title":"J Liquid Chromatogr Relat Tech"},{"key":"R26-20260508","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/jat\/21.2.105","article-title":"Plasma concentrations of heroin and morphine-related metabolites after intranasal and intramuscular administration","volume":"21","author":"Skopp","year":"1997","journal-title":"J Anal Toxicol"},{"key":"R27-20260508","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2143\/ACB.3323","article-title":"Plasma level monitoring of the major metabolites of diacetylmorphine (heroin) by the \u201cchasing the dragon\u201d route in severe heroin addicts","volume":"68","author":"Dubois","year":"2013","journal-title":"Acta Clin Belg"},{"key":"R28-20260508","doi-asserted-by":"crossref","first-page":"124104","DOI":"10.1016\/j.jchromb.2024.124104","article-title":"Development and validation of an LC-MS\/MS method for quantifying diamorphine and its major metabolites 6-monoacetylmorphine, morphine, morphine-3-glucuronide, and morphine-6-glucuronide in human plasma","volume":"1237","author":"Thomann","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R29-20260508","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/jat\/31.7.388","article-title":"Microwave-assisted extraction and HPLC-DAD determination of drugs of abuse in human plasma","volume":"31","author":"Fern\u00e1ndez","year":"2007","journal-title":"J Anal Toxicol"},{"key":"R30-20260508","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/anatox\/35.8.577","article-title":"Ultra-performance liquid chromatography-tandem mass spectrometry method for the analysis of amphetamines in plasma","volume":"35","author":"Fern\u00e1ndez","year":"2011","journal-title":"J Anal Toxicol"},{"key":"R31-20260508","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jat\/23.1.67","article-title":"Toxicological findings in a fatal ingestion of methamphetamine","volume":"23","author":"Molina","year":"1999","journal-title":"J Anal Toxicol"},{"key":"R32-20260508","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/jat\/30.8.501","article-title":"Major and minor metabolites of cocaine in human plasma following controlled subcutaneous cocaine administration","volume":"30","author":"Kolbrich","year":"2006","journal-title":"J Anal Toxicol"},{"key":"R33-20260508","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jat\/bkx085","article-title":"Comparison of cocaine\/crack biomarkers concentrations in oral fluid, urine and plasma simultaneously collected from drug users","volume":"42","author":"Fiorentin","year":"2018","journal-title":"J Anal Toxicol"},{"key":"R34-20260508","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jat\/22.1.6","article-title":"Drug testing with alternative matrices I. Pharmacological effects and disposition of cocaine and codeine in plasma, sebum, and stratum corneum","volume":"22","author":"Joseph","year":"1998","journal-title":"J Anal Toxicol"},{"key":"R35-20260508","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/molecules25051046","article-title":"Blood and plasma volumetric absorptive microsampling (VAMS) coupled to LC-MS\/MS for the forensic assessment of cocaine consumption","volume":"25","author":"Mandrioli","year":"2020","journal-title":"Molecules"},{"key":"R36-20260508","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.forsciint.2010.03.032","article-title":"Cocaine and benzoylecgonine concentrations in fluorinated plasma samples of drivers under suspicion of driving under influence","volume":"200","author":"Musshoff","year":"2010","journal-title":"Forensic Sci Int"},{"key":"R37-20260508","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0b013e3181f2b729","article-title":"Pharmacokinetics of cocaine and metabolites in human oral fluid and correlation with plasma concentrations after controlled administration","volume":"32","author":"Scheidweiler","year":"2010","journal-title":"Ther Drug Monit"},{"key":"R38-20260508","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1093\/jat\/25.7.497","article-title":"A validated liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry method for quantitation of cocaine and benzoylecgonine in human plasma","volume":"25","author":"Lin","year":"2001","journal-title":"J Anal Toxicol"},{"key":"R39-20260508","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1093\/jat\/26.7.382","article-title":"Correlation between pharmacological effects and plasma cocaine concentrations after smoked administration","volume":"26","author":"Jenkins","year":"2002","journal-title":"J Anal Toxicol"},{"key":"R40-20260508","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/jat\/34.6.319","article-title":"Ethyl glucuronide concentrations in oral fluid, blood, and urine after volunteers drank 0.5 and 1.0 g\/kg doses of ethanol","volume":"34","author":"H\u00f8iseth","year":"2010","journal-title":"J Anal Toxicol"},{"key":"R41-20260508","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1093\/alcalc\/agn035","article-title":"Value of ethyl glucuronide in plasma as a biomarker for recent alcohol consumption in the emergency room","volume":"43","author":"Neumann","year":"2008","journal-title":"Alcohol Alcohol"},{"key":"R42-20260508","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/FTD.0b013e3180307e5e","article-title":"Disposition of gamma-hydroxybutyric acid in conventional and nonconventional biologic fluids after single drug administration: issues in methodology and drug monitoring","volume":"29","author":"Abanades","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R43-20260508","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1365-2125.1992.tb04129.x","article-title":"Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses","volume":"34","author":"Ferrara","year":"1992","journal-title":"Br J Clin Pharmacol"},{"key":"R44-20260508","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF00265954","article-title":"Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers","volume":"45","author":"Palatini","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"key":"R45-20260508","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/sleep\/21.5.507","article-title":"Pharmacokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients","volume":"21","author":"Scharf","year":"1998","journal-title":"Sleep"},{"key":"R46-20260508","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jat\/28.8.625","article-title":"Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects","volume":"28","author":"Brenneisen","year":"2004","journal-title":"J Anal Toxicol"},{"key":"R47-20260508","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s002280050113","article-title":"Effect of moderate or severe liver dysfunction on the pharmacokinetics of \u03b3-hydroxybutyric acid","volume":"50","author":"Ferrara","year":"1996","journal-title":"Eur J Clin Pharmacol"},{"key":"R48-20260508","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1196\/annals.1369.065","article-title":"Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics","volume":"1074","author":"Abanades","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"R49-20260508","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/0091270002239707","article-title":"The influence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects","volume":"43","author":"Borgen","year":"2003","journal-title":"J Clin Pharmacol"},{"key":"R50-20260508","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/0091270003262795","article-title":"The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients","volume":"44","author":"Borgen","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"R51-20260508","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/bdd.336","article-title":"Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers","volume":"24","author":"Yanagihara","year":"2003","journal-title":"Biopharm Drug Dispos"},{"key":"R52-20260508","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00044011-200929050-00004","article-title":"Development of a sublingual\/oral formulation of ketamine for use in neuropathic pain: preliminary findings from a three-way randomized, crossover study","volume":"29","author":"Chong","year":"2009","journal-title":"Clin Drug Investig"},{"key":"R53-20260508","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bcp.12264","article-title":"The absolute bioavailability of racemic ketamine from a novel sublingual formulation","volume":"77","author":"Rolan","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"R54-20260508","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1007\/s00216-013-6848-7","article-title":"Oral fluid and plasma 3,4-methylenedioxymethamphetamine (MDMA) and metabolite correlation after controlled oral MDMA administration","volume":"405","author":"Desrosiers","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"R55-20260508","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00216-013-7468-y","article-title":"3,4-Methylenedioxymethamphetamine (MDMA) and metabolites disposition in blood and plasma following controlled oral administration","volume":"406","author":"Hartman","year":"2014","journal-title":"Anal Bioanal Chem"},{"key":"R56-20260508","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/FTD.0b013e3181684fa0","article-title":"Plasma pharmacokinetics of 3,4-methylenedioxymethamphetamine after controlled oral administration to young adults","volume":"30","author":"Kolbrich","year":"2008","journal-title":"Ther Drug Monit"},{"key":"R57-20260508","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1373\/49.1.121","article-title":"Methamphetamine and amphetamine pharmacokinetics in oral fluid and plasma after controlled oral methamphetamine administration to human volunteers","volume":"49","author":"Schepers","year":"2003","journal-title":"Clin Chem"},{"key":"R58-20260508","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF00265969","article-title":"Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration","volume":"38","author":"Peterson","year":"1990","journal-title":"Eur J Clin Pharmacol"},{"key":"R59-20260508","doi-asserted-by":"crossref","first-page":"266","DOI":"10.2165\/00003088-198207030-00006","article-title":"Patient-controlled analgesic therapy, part IV: pharmacokinetics and analgesic plasma concentrations of morphine","volume":"7","author":"Dahlstr\u00f6m","year":"1982","journal-title":"Clin Pharmacokinet"},{"key":"R60-20260508","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1002\/cpt197824160","article-title":"Plasma codeine and morphine concentrations after therapeutic oral doses of codeine-containing analgesics","volume":"24","author":"Findlay","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"R61-20260508","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/j.1552-4604.1986.tb03526.x","article-title":"Pharmacokinetics and clinical effects of alprazolam following single and multiple oral doses in patients with panic disorder","volume":"26","author":"Ciraulo","year":"1986","journal-title":"J Clin Pharmacol"},{"key":"R62-20260508","doi-asserted-by":"crossref","first-page":"64.e1","DOI":"10.1016\/j.ajog.2016.09.095","article-title":"Dose-adjusted plasma concentrations of sublingual buprenorphine are lower during than after pregnancy","volume":"216","author":"Bastian","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"R63-20260508","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0376-8716(98)00192-6","article-title":"Plasma concentrations of buprenorphine 24 to 72 hours after dosing","volume":"55","author":"Chawarski","year":"1999","journal-title":"Drug Alcohol Depend"},{"key":"R64-20260508","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"R65-20260508","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40268-019-0277-9","article-title":"Pharmacokinetics of sublingual buprenorphine tablets following single and multiple doses in Chinese participants with and without opioid use disorder","volume":"19","author":"Dong","year":"2019","journal-title":"Drugs R D"},{"key":"R66-20260508","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1093\/clinchem\/43.12.2292","article-title":"Subnanogram-concentration measurement of buprenorphine in human plasma by electron-capture capillary gas chromatography: application to pharmacokinetics of sublingual buprenorphine","volume":"43","author":"Everhart","year":"1997","journal-title":"Clin Chem"},{"key":"R67-20260508","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/jat\/25.6.486","article-title":"Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate","volume":"25","author":"Kronstrand","year":"2001","journal-title":"J Anal Toxicol"},{"key":"R68-20260508","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jat\/23.6.452","article-title":"Correlation of saliva codeine concentrations with plasma concentrations after oral codeine administration","volume":"23","author":"O'Neal","year":"1999","journal-title":"J Anal Toxicol"},{"key":"R69-20260508","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/clpt.1992.123","article-title":"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time","volume":"52","author":"Friedman","year":"1992","journal-title":"Clin Pharmacol Ther"},{"key":"R70-20260508","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/BF00426470","article-title":"Benzodiazepine overdosage: plasma concentrations and clinical outcome","volume":"73","author":"Divoll","year":"1981","journal-title":"Psychopharmacology (Berl)"},{"key":"R71-20260508","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.talanta.2014.11.052","article-title":"Chiral on-line solid phase extraction coupled to liquid chromatography-tandem mass spectrometry assay for quantification of (R) and (S) enantiomers of methadone and its main metabolite in plasma","volume":"134","author":"Bouqui\u00e9","year":"2015","journal-title":"Talanta"},{"key":"R72-20260508","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1093\/jat\/bku096","article-title":"Quantitation of methadone and metabolite in patients under maintenance treatment","volume":"38","author":"Diong","year":"2014","journal-title":"J Anal Toxicol"},{"key":"R73-20260508","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF00194951","article-title":"Pharmacokinetics of methadone and its primary metabolite in 20 opiate addicts","volume":"48","author":"de Vos","year":"1995","journal-title":"Eur J Clin Pharmacol"},{"key":"R74-20260508","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0376-8716(98)00096-9","article-title":"Plasma methadone concentrations as an indicator of opioid withdrawal symptoms and heroin use in a methadone maintenance program","volume":"52","author":"Torrens","year":"1998","journal-title":"Drug Alcohol Depend"},{"key":"R75-20260508","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3109\/15563659609013815","article-title":"Gabapentin, valproic acid, and ethanol intoxication: elevated blood levels with mild clinical effects","volume":"34","author":"Fern\u00e1ndez","year":"1996","journal-title":"J Toxicol Clin Toxicol"},{"key":"R76-20260508","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jemermed.2014.04.044","article-title":"Extracorporeal life support and plasmapheresis in a case of severe polyintoxication","volume":"47","author":"Koschny","year":"2014","journal-title":"J Emerg Med"},{"key":"R77-20260508","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1556\/1326.2023.01104","article-title":"Validation of the rapid and simple LC-MS\/MS method for the quantification of pregabalin in plasma of acutely poisoned patients","volume":"36","author":"Antunovic","year":"2024","journal-title":"Acta Chromatographica"},{"key":"R78-20260508","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/01.ftd.0000158874.54100.1a","article-title":"Analysis of pregabalin at therapeutic concentrations in human plasma\/serum by reversed-phase HPLC","volume":"27","author":"Berry","year":"2005","journal-title":"Ther Drug Monit"},{"key":"R79-20260508","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1365\/s10337-007-0440-2","article-title":"Determination of pregabalin in human plasma using LC-MS-MS","volume":"67","author":"Mandal","year":"2008","journal-title":"Chromatographia"},{"key":"R80-20260508","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s13181-010-0052-3","article-title":"Significant pregabalin toxicity managed with supportive care alone","volume":"6","author":"Wood","year":"2010","journal-title":"J Med Toxicol"},{"key":"R81-20260508","first-page":"162","article-title":"A case of pregabalin intoxication","volume":"23","author":"Miljevic","year":"2012","journal-title":"Psychiatriki"},{"key":"R82-20260508","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/FTD.0000000000000541","article-title":"An improved LC-ESI-MS\/MS method to quantify pregabalin in human plasma and dry plasma spot for therapeutic monitoring and pharmacokinetic applications","volume":"40","author":"Dwivedi","year":"2018","journal-title":"Ther Drug Monit"},{"key":"R83-20260508","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/a-0600-2113","article-title":"Saliva versus plasma therapeutic drug monitoring of pregabalin in Jordanian patients","volume":"68","author":"Idkaidek","year":"2018","journal-title":"Drug Res (Stuttg)"},{"key":"R84-20260508","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1515\/dmpt-2017-0040","article-title":"Correlation between plasma concentrations of tramadol and its metabolites and the incidence of seizure in tramadol-intoxicated patients","volume":"33","author":"Ahmadimanesh","year":"2018","journal-title":"Drug Metab Pers Ther"},{"key":"R85-20260508","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/bmc.135","article-title":"Validation of a high-performance liquid chromatographic method for the enantiospecific quantitation of zopiclone in plasma","volume":"16","author":"Gebauer","year":"2002","journal-title":"Biomed Chromatogr"},{"key":"R86-20260508","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0090-9556(25)08209-1","article-title":"Pharmacokinetics of zopiclone and its enantiomers in Caucasian young healthy volunteers","volume":"21","author":"Fernandez","year":"1993","journal-title":"Drug Metab Dispos"},{"issue":"suppl 2","key":"R87-20260508","first-page":"76","article-title":"Pharmacokinetics and metabolism of zopiclone","volume":"27","author":"Gaillot","year":"1983","journal-title":"Pharmacology"},{"key":"R88-20260508","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1309\/AJCPN5BMTSF1CDYP","article-title":"Establishing reference intervals for clinical laboratory test results: is there a better way?","volume":"133","author":"Katayev","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"R89-20260508","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1080\/10408363.2018.1499708","article-title":"Sample management for clinical biochemistry assays: are serum and plasma interchangeable specimens?","volume":"55","author":"Lima-Oliveira","year":"2018","journal-title":"Crit Rev Clin Lab Sci"},{"key":"R90-20260508","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fphar.2025.1660323","article-title":"Are plasma drug concentrations still necessary? Rethinking the pharmacokinetic link in dose-response relationships","volume":"16","author":"Simon","year":"2025","journal-title":"Front Pharmacol"},{"key":"R91-20260508","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/jat\/27.8.533","article-title":"Mechanisms underlying postmortem redistribution of drugs: a review","volume":"27","author":"P\u00e9lissier-Alicot","year":"2003","journal-title":"J Anal Toxicol"},{"key":"R92-20260508","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0379-0738(90)90182-X","article-title":"Post-mortem drug redistribution\u2014a toxicological nightmare","volume":"45","author":"Pounder","year":"1990","journal-title":"Forensic Sci Int"},{"key":"R93-20260508","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1055\/s-0037-1600991","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"R94-20260508","first-page":"e191","article-title":"Laboratory-generated urine toxicology interpretations: a mixed methods study","volume":"24","author":"Chua","year":"2021","journal-title":"Pain Physician"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T09:44:37Z","timestamp":1778579077000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":90,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001471","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"2025-12-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}